Ligand Pharmaceuticals Incorporated (LGND) Q1 FY26 Earnings Call

Royalty revenue grew 56% year over year, while Zoma is expected to add $0.50 EPS in 2026.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Length44 minutes
EPS$-0.67
Revenue$51.7M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25 · Q2 FY25

All LGND earnings · Back to LGND overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.